Close Menu

Colorectal Cancer

News and reporting on colorectal cancer.

The results from the Australian study may have implications for US consumers, since similar to Australia, US law bars health insurers from discriminating based on genetic information, but not companies providing life and disability insurance.

"If approved by the FDA, the DxS TheraScreen: K-RAS Mutation Kit would become a companion diagnostic for use with Erbitux in metastatic colorectal cancer to determine which patients have wild-type KRAS status in the US," DxS said this week.

The companies aim to offer the K-RAS mutation companion test to US markets.

The company also reported its financial results for the first half of 2009, posting a roughly 32 percent rise in revenues and a 28 percent jump in net losses.

A Phase III prospective study shows Vectibix combined with an irinotecan-based chemotherapy regimen improves progression-free survival in patients with wild-type KRAS tumors compared to chemotherapy alone. The study did not reach statistical significance for showing improvement in overall survival, however.

According to the company, the patents cover "methods for the algorithms used and methods utilizing genes beyond the current 21 gene set."

Testing colorectal cancer patients for their UGT1A1*28 status before prescribing irinotecan is cost-effective only when reduced doses of the drug are as effective as full doses in patients who are homozygous for the variant.

Pfizer enlisted the help of Ontario researchers to find molecular signatures that can be used to personalize treatments in its pipeline for colorectal cancer.

In order to make the labeling change, the agency reviewed retrospective data from seven clinical trials. But this is the exception, according to one official from a diagnostic company who believes FDA's lengthy deliberations have further nudged drug companies to advance diagnostics at the same time as therapeutics in prospective studies.

The FDA has updated the drugs' labels to note that "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benefit for the EGFR inhibitors in patients whose tumors had KRAS mutations in codon 12 or 13" and that the use of the drugs is not recommended for the treatment of colorectal cancer patients with these mutations.

Pages

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.